Anteris Technologies Global Quick Ratio (AVR) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Anteris Technologies Global Corp   (AVR)

Anteris Technologies Global 's Quick Ratio

AVR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 11.37 above Anteris Technologies Global Corp average.

Within Medical Equipment & Supplies industry 5 other companies have achieved higher Quick Ratio than Anteris Technologies Global in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 0 to 283.

Explain Quick Ratio?
How much Cash & cash equivalents AVR´s has?
What are AVR´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AVR/financial-strength
https://api.csimarket.com/api/v1/companies/AVR/fundamentals
https://api.csimarket.com/api/v1/companies/AVR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
AVR Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 49.16 %
Y / Y Cash & cash equivalent Change -
Quick Ratio MRQ 11.37
AVR's Total Ranking # 283
Seq. Current Liabilities Change 3.95 %
Seq. Cash & cash equivalent Change -15.7 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 6
Healthcare Sector # 110
Overall Market # 283


Quick Ratio Statistics
High Average Low
14.02 7.36 3.52
(Jun 30 2026)   (Mar 31 2025)




Financial Statements
Anteris Technologies Global 's Current Liabilities $ 19 Millions Visit AVR's Balance sheet
Anteris Technologies Global 's Cash & cash equivalent $ 217 Millions Visit AVR's Balance sheet
Source of AVR's Sales Visit AVR's Sales by Geography


Cumulative Anteris Technologies Global 's Quick Ratio

AVR's Quick Ratio for the trailling 12 Months

AVR Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 25.46 %
Y / Y Cash & cash equivalent TTM Growth 302.86 %
Quick Ratio TTM 7.71
Total Ranking TTM # 3647
Seq. Current Liabilities TTM Growth 11.22 %
Seq. Cash & cash equivalent TTM Growth 82.17 %


On the trailing twelve months basis AVR Cash & cash equivalent fell by -15.7 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Anteris Technologies Global 's Quick Ratio to 7.71, above AVR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 193 other companies have achieved higher Quick Ratio than Anteris Technologies Global . While Quick Ratio overall ranking has improved so far to 3647, from total ranking during the twelve months ending second quarter 2026 at 3963.

Explain Quick Ratio?
How much Cash & cash equivalents AVR´s has?
What are AVR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Equipment & Supplies Industry # 194
Healthcare Sector # 865
Within the Market # 3647


trailing twelve months Quick Ratio Statistics
High Average Low
5.28 2.86 1.24
(Jun 30 2026)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Equipment & Supplies Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Bone Biologics Corporation  12.66 $ 6.088  Millions$ 0.481  Millions
Vivos Inc  11.65 $ 1.807  Millions$ 0.155  Millions
Anteris Technologies Global Corp   11.37 $ 216.987  Millions$ 19.085  Millions
Lemaitre Vascular Inc   11.26 $ 389.721  Millions$ 34.620  Millions
Mobia Medical Inc   10.63 $ 160.692  Millions$ 15.115  Millions
Axogen inc   9.55 $ 348.068  Millions$ 36.456  Millions
Delcath Systems Inc   8.01 $ 104.315  Millions$ 13.022  Millions
Orchestra Biomed Holdings Inc   7.16 $ 101.907  Millions$ 14.228  Millions
Envveno Medical Corporation  7.13 $ 18.472  Millions$ 2.589  Millions
Ceribell Inc   6.51 $ 117.467  Millions$ 18.034  Millions
Autonomix Medical Inc   6.13 $ 7.692  Millions$ 1.254  Millions
Iradimed Corporation  6.13 $ 63.288  Millions$ 10.323  Millions
Orasure Technologies Inc  5.90 $ 148.238  Millions$ 25.104  Millions
Perspective Therapeutics Inc   5.09 $ 201.695  Millions$ 39.602  Millions
Beyond Air Inc   4.69 $ 17.121  Millions$ 3.647  Millions
Clearpoint Neuro Inc   4.68 $ 46.184  Millions$ 9.869  Millions
Cvrx inc   4.67 $ 58.746  Millions$ 12.583  Millions
Heartbeam Inc   4.47 $ 6.065  Millions$ 1.358  Millions
Dexcom Inc   4.25 $ 964.800  Millions$ 227.000  Millions
Innovative Eyewear Inc   3.86 $ 3.197  Millions$ 0.829  Millions
Sight Sciences Inc   3.84 $ 77.402  Millions$ 20.137  Millions
Bluejay Diagnostics Inc  3.83 $ 7.380  Millions$ 1.927  Millions
Alpha Pro Tech Ltd   3.78 $ 25.546  Millions$ 6.750  Millions
Hyperfine Inc   3.60 $ 37.872  Millions$ 10.532  Millions
Capsovision Inc   3.55 $ 21.757  Millions$ 6.124  Millions
Profound Medical Corp   3.41 $ 33.343  Millions$ 9.771  Millions
Rxsight Inc   3.40 $ 254.683  Millions$ 74.952  Millions
Omada Health Inc   3.23 $ 243.151  Millions$ 75.379  Millions
Transmedics Group Inc   3.22 $ 492.962  Millions$ 152.857  Millions
Trisalus Life Sciences Inc   3.15 $ 41.057  Millions$ 13.014  Millions

Date modified: 2026-11-12T06:02:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.